// App-Quantinova.ai

P138 : Phase III study of carboplatin-paclitaxel/nab-paclitaxel chemotherapy with or without pembrolizumab for first-line metastatic, squamous nonsmall cell lung carcinoma: KEYNOTE-407

Researchers

Presenter

  • Edward B. Garon

Principal Investigators

  • N/A

Medical Centers

  • Gabinete Radiologico del Dr. Pita, NA, Madrid, Spain

  • The Crown Princess Mary Cancer Centre Westmead, Westmead, New South Wales, Australia

  • Princess Margaret Cancer Center, Toronto, ON, Canada

Locations

  • Spain

  • Canada

  • Australia

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lung Cancer

  • Non Small Cell Lung cancer

Biomarkers

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pembrolizumab

  • Carboplatin

  • Paclitaxel

  • taxane

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved